JP2021167329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021167329A5 JP2021167329A5 JP2021109873A JP2021109873A JP2021167329A5 JP 2021167329 A5 JP2021167329 A5 JP 2021167329A5 JP 2021109873 A JP2021109873 A JP 2021109873A JP 2021109873 A JP2021109873 A JP 2021109873A JP 2021167329 A5 JP2021167329 A5 JP 2021167329A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell
- nucleic acid
- permeable
- phosphorothioate nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 102000039446 nucleic acids Human genes 0.000 claims 28
- 108020004707 nucleic acids Proteins 0.000 claims 28
- -1 phosphorothioate nucleic acid Chemical class 0.000 claims 20
- 230000003834 intracellular effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202006P | 2015-08-06 | 2015-08-06 | |
| US62/202,006 | 2015-08-06 | ||
| JP2018506182A JP7104462B2 (ja) | 2015-08-06 | 2016-08-05 | 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506182A Division JP7104462B2 (ja) | 2015-08-06 | 2016-08-05 | 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021167329A JP2021167329A (ja) | 2021-10-21 |
| JP2021167329A5 true JP2021167329A5 (enExample) | 2021-12-09 |
| JP7260596B2 JP7260596B2 (ja) | 2023-04-18 |
Family
ID=57943680
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506182A Active JP7104462B2 (ja) | 2015-08-06 | 2016-08-05 | 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法 |
| JP2021109873A Active JP7260596B2 (ja) | 2015-08-06 | 2021-07-01 | 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506182A Active JP7104462B2 (ja) | 2015-08-06 | 2016-08-05 | 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11661463B2 (enExample) |
| EP (1) | EP3331543A4 (enExample) |
| JP (2) | JP7104462B2 (enExample) |
| CN (2) | CN114306627A (enExample) |
| AR (1) | AR105642A1 (enExample) |
| TW (1) | TW201718023A (enExample) |
| WO (1) | WO2017024238A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11661463B2 (en) * | 2015-08-06 | 2023-05-30 | City Of Hope | Cell penetrating protein-antibody conjugates and methods of use |
| CN108866635B (zh) * | 2017-05-09 | 2021-11-26 | 安升（上海）医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
| WO2019014648A1 (en) | 2017-07-13 | 2019-01-17 | City Of Hope | PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE |
| KR102526768B1 (ko) * | 2017-12-22 | 2023-04-27 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체 |
| WO2019125033A1 (ko) * | 2017-12-22 | 2019-06-27 | (주)로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물 |
| KR102256985B1 (ko) | 2019-06-25 | 2021-06-03 | 주식회사 로피바이오 | 항 stat3 특이 항체 및 이를 포함하는 약학적 조성물 |
| US20240110176A1 (en) * | 2020-05-22 | 2024-04-04 | City Of Hope | Phosphorothioate nucleic acid conjugates including dna editing enzymes |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| WO2024129459A1 (en) | 2022-12-16 | 2024-06-20 | University Of Rochester | Repairmen! of barrier dysfunction in esophagus |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| AU2006325030B2 (en) * | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| WO2009012356A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Imaging nucleic acid binding proteins |
| EP2090584A1 (en) * | 2008-02-13 | 2009-08-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Identification of a novel cysteine-rich cell penetrating peptide |
| AU2009234266B2 (en) | 2008-04-11 | 2015-08-06 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP2611927B1 (en) * | 2010-08-31 | 2018-08-01 | Sirna Therapeutics, Inc. | Novel single chemical entities and methods for delivery of oligonucleotides |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| EP3514236A1 (en) * | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| CA2922698C (en) * | 2013-08-29 | 2023-01-03 | City Of Hope | Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids |
| CA2972986A1 (en) * | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
| US11661463B2 (en) * | 2015-08-06 | 2023-05-30 | City Of Hope | Cell penetrating protein-antibody conjugates and methods of use |
-
2016
- 2016-08-05 US US15/750,814 patent/US11661463B2/en active Active
- 2016-08-05 EP EP16833941.4A patent/EP3331543A4/en active Pending
- 2016-08-05 CN CN202210151646.4A patent/CN114306627A/zh active Pending
- 2016-08-05 WO PCT/US2016/045817 patent/WO2017024238A1/en not_active Ceased
- 2016-08-05 JP JP2018506182A patent/JP7104462B2/ja active Active
- 2016-08-05 TW TW105124954A patent/TW201718023A/zh unknown
- 2016-08-05 CN CN201680058266.9A patent/CN108135958B/zh active Active
- 2016-08-08 AR ARP160102425A patent/AR105642A1/es unknown
-
2021
- 2021-07-01 JP JP2021109873A patent/JP7260596B2/ja active Active
-
2023
- 2023-04-11 US US18/298,933 patent/US20230250196A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021167329A5 (enExample) | ||
| JP2018525381A5 (enExample) | ||
| US7790140B2 (en) | Compositions for delivery of therapeutics and other materials, and methods of making and using the same | |
| Lee et al. | Therapeutic aptamers: developmental potential as anticancer drugs | |
| JP5600846B2 (ja) | キトサン基材高分子接合体及びその製造方法 | |
| R Kanwar et al. | Nucleic acid-based aptamers: applications, development and clinical trials | |
| JP2021152022A5 (enExample) | ||
| JP2018525001A5 (enExample) | ||
| JP2019522490A5 (enExample) | ||
| JP2020505330A5 (enExample) | ||
| JP2019513692A (ja) | 核酸キャリア及び治療上の使用方法 | |
| JP2011530537A5 (enExample) | ||
| JP2013513377A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2018505870A5 (enExample) | ||
| WO2017205277A2 (en) | Methods for using nucleic acid aptamers for directed templated assembly | |
| JP2022542198A (ja) | アプタマーベース多重特異性治療剤 | |
| Liu et al. | Nanoparticle delivery: targeting and nonspecific binding | |
| JP5991535B2 (ja) | アミロイドタンパク質オリゴマー結合アプタマー | |
| JP2018512858A (ja) | 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害 | |
| JP2016513089A (ja) | 細胞への遺伝子送達のための機能性ｄｎａデンドリマー | |
| US20210292760A1 (en) | Aptamer-Based CAR T-Cell Switch | |
| JPWO2020011974A5 (enExample) | ||
| JP2023532032A (ja) | 血液脳関門浸透アプタマー及びその利用 | |
| CN113122543A (zh) | 唾液酸结合性免疫球蛋白样凝集素-15蛋白的核酸适配体及其应用 |